Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Colorectal Neoplasms 56 Ovarian Neoplasms 35 Carcinoma, Hepatocellular 35 Neoplasms 25 Fallopian Tube Neoplasms 20 Carcinoma, Non-Small-Cell Lung 19 Endometrial Neoplasms 13 Glioblastoma 11 Breast Neoplasms 11 Brain Neoplasms 11 Neoplasm Metastasis 9 Colonic Neoplasms 9 Lung Neoplasms 8 Uterine Cervical Neoplasms 7 Liver Neoplasms 7 Rectal Neoplasms 6 Glioma 6 Biliary Tract Neoplasms 6 Stomach Neoplasms 5 Triple Negative Breast Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Gastrointestinal Neoplasms 4 Digestive System Neoplasms 4 Carcinoma, Ovarian Epithelial 4 Small Cell Lung Carcinoma 3 Sarcoma 3 Recurrence 3 Peritoneal Neoplasms 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Pancreatic Neoplasms 3

Interventions

pembrolizumab 4 atezolizumab 3 Cetuximab 3 olaparib 2 Trastuzumab 2 Docetaxel 2 zimberelimab 1 tocilizumab 1 spartalizumab 1 ribociclib 1 pralsetinib 1 pertuzumab 1 pegylated granulocyte colony-stimulating factor 1 ipatasertib 1 inavolisib 1 fludarabine phosphate 1 fludarabine 1 entrectinib 1 encorafenib 1 cemiplimab 1 binimetinib 1 anlotinib 1 amivantamab 1 alectinib 1 adagrasib 1 Pemetrexed 1 Oxaliplatin 1 Nivolumab 1 Leucovorin 1 Irinotecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Solid Tumors × Bevacizumab × 90 days × Clear all

NCT05101070 2026-03-18

aCCeleR8-001

Shionogi Inc.

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡